INTERLAB has Changed its Company Name to synlab Pharma Institute
In 2014 synlab services GmbH purchased INTERLAB GmbH central lab services – worldwide (INTERLAB). In September, INTERLAB merged with synlab Umweltinstitut GmbH, and consequently all documentation carries the synlab logo and will refer to the synlab pharma institute, Munich location, a division of synlab Umweltinstitut GmbH.
Please note that Dr. Hermann Schulz, Chief Executive Officer of INTERLAB until August 31st, 2015, will continue as a Legal Representative (“Prokurist”) of synlab Umweltinstitut GmbH. He will also head the synlab pharma institute as its Executive Vice President.
INTERLAB and synlab have been successfully cooperating since 2004. Hence, no impact on the day to day business or on the handling of study samples is to be expected. Our address, shipping logistics, and contractual terms shall not undergo any modifications. Although email addresses will switch form name@interlab.de to name@synlab.com your messages will automatically be re-routed.
As the new contractual partner, synlab Umweltinstitut GmbH shall overtake all duties and responsibilities of INTERLAB. Although invoices will be issued by synlab Umweltinstitut GmbH (using their tax ID: DE 195 993 312) the bank account at Deutsche Bank AG MuÌnchen will remain unchanged by the moment.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025